Attached files
| file | filename |
|---|---|
| 10-K - 10-K - Karyopharm Therapeutics Inc. | d113778d10k.htm |
| EX-32.1 - EX-32.1 - Karyopharm Therapeutics Inc. | d113778dex321.htm |
| EX-23.1 - EX-23.1 - Karyopharm Therapeutics Inc. | d113778dex231.htm |
| EX-21.1 - EX-21.1 - Karyopharm Therapeutics Inc. | d113778dex211.htm |
| EX-31.1 - EX-31.1 - Karyopharm Therapeutics Inc. | d113778dex311.htm |
| EX-12.1 - EX-12.1 - Karyopharm Therapeutics Inc. | d113778dex121.htm |
| EX-31.2 - EX-31.2 - Karyopharm Therapeutics Inc. | d113778dex312.htm |
Exhibit 23.2
CONSENT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM
We consent to the incorporation by reference in Registration Statements (Nos. 333-194746 and 333-202742) on Form S-8 and Registration Statement (No. 333-201366) on Form S-3 of Karyopharm Therapeutics Inc. of our report dated March 21, 2014, relating to our audit of the consolidated statements of operations, comprehensive loss, convertible preferred stock and stockholders’ equity (deficit), and cash flows for the year ended December 31, 2013, which appear in this Annual Report on Form 10-K of Karyopharm Therapeutics Inc. for the year ended December 31, 2015.
/s/ RSM US LLP
Boston, Massachusetts
March 15, 2016